Home Newsfeeds Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase

byBenzinga Newsdesk

April 24, 2024

1 minute read

investors.precigen.com/events-presentations.

UPDATE: MicroStrategy Q4 Adj. EPS $(20.51) May Not Compare To $(0.13) Estimate, Sales $132.55M Beat $131.33M Estimate

By Happy Mohamed

February 2, 5:54 PM

MicroStrategy (NASDAQ:MSTR) reported quarterly losses of $(20.51) per share which missed the analyst consensus estimate of $(0.13) by 15676.92 percent. This is a 143.88 percent decrease over losses of $(8.41) per share from the same period last year.

MSTR

Cenovus Energy Q2 EPS $1.19 Beats $0.82 Estimate

By Bill Haddad

July 28, 6:09 AM

Cenovus Energy (NYSE:CVE) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $0.82 by 45.12 percent. This is a 1222.22 percent increase over earnings of $0.09 per share from the

CVE

Meta Selects Qualcomm To Accomplish Metaverse Ambitions

By Anusuya Lahiri

September 2, 7:41 AM

Facebook parent Meta Platforms Inc (NASDAQ:META) agreed to use Qualcomm Inc (NASDAQ:QCOM) produced custom chipsets for its Quest virtual reality devices at…